Onco-neurology: a clinical perspective on cancer-associated neurological complications Authors: Yaying Song, Wenbin Wan, Ying Zhang, Gang Wang Published: 2026 ABSTRACT Advances in cancer screening and treatment have improved survival, while neurological complications in patients with cancer are gaining clinical relevance. Many of these complications are not attributable to direct tumor invasion, compression, or metastasis, but rather reflect immune-mediated mechanisms, treatment exposure, systemic disturbances, or tumor-associated biological processes. They are commonly discussed under categories such as paraneoplastic neurological syndromes, treatment-related neurotoxicity, immune-related adverse events, or related disorders. However, these categories often overlap and require integrated assessment across oncology and neurology. In this Correspondence, we propose “onco-neurology” as a term to describe cancer-associated neurological complications that extend beyond direct nervous system involvement. This concept complements neuro-oncology and paraneoplastic neurological syndromes by emphasizing treatment-related, immune-mediated, systemic, and mixed neurological disorders. Recognition of this field may reduce diagnostic fragmentation, support multidisciplinary evaluation, and promote tumor–immune–neural research. Advances in cancer screening and treatment have improved survival; nevertheless, neurological complications increasingly affect treatment continuity, quality of life, and long-term outcomes. These problems are often categorized as paraneoplastic neurological syndromes, treatment-related neurotoxicity, immune-related neurological adverse events, or procedure-related neurological injury. Yet many share a common feature: they occur in patients with cancer but are not caused by direct tumor invasion of the nervous system. Instead, they reflect immune responses, treatment exposure, systemic disturbances, or tumor-associated biological processes. In clinical practice, this distinction is not always clear—particularly when neurological symptoms arise during active malignancy or anticancer therapy. Here, we propose “onco-neurology” as a name for this field [1]. This term is not intended to replace neuro-oncology or paraneoplastic neurological syndromes. Neuro-oncology primarily addresses tumors involving the nervous system itself, including primary and metastatic disease, whereas paraneoplastic neurological syndromes focuses on immune-mediated neurological syndromes associated with cancer [2]. Onco-neurology has a broader scope, encompassing neurological complications that extend beyond direct tumor involvement—particularly when paraneoplastic, treatment-related, immune-mediated, systemic, or tumor–neural mechanisms overlap. Its proposed clinical scope is summarized in Table 1. Clinically, subacute ataxia, encephalopathy, or peripheral neuropathy arising during cancer treatment may require evaluation for metastasis, paraneoplastic disease, treatment toxicity, immune-related neurotoxicity, infection, and metabolic disturbances. Such assessments depend on cancer status, treatment timing, neurological phenotype, antibody or cerebrospinal fluid findings, electrophysiology, and imaging. In this context, onco-neurology helps distinguish direct tumor involvement from neurological disorders related to cancer immunity, treatment exposure, systemic illness, or tumor–neural interactions. The practical value of this term lies in clinical attribution. Neurological symptoms in patients with cancer may be attributed to metastasis, treatment intolerance, or an unrelated disorder, while immune-mediated or otherwise treatable mechanisms are overlooked. This is particularly relevant when decisions regarding continuation, modification, or discontinuation of anticancer therapy depend on the underlying cause of neurological injury. For example, subacute encephalopathy during immunotherapy may involve metastasis, infection, metabolic disturbance, immune checkpoint inhibitor-associated encephalitis, or paraneoplastic neurological syndromes. Similarly, progressive neuropathy following chemotherapy may reflect cumulative neurotoxicity, but nutritional, metabolic, autoimmune, or recurrent cancer-related causes should also be considered. These scenarios illustrate why multidisciplinary assessment is often necessary. Onco-neurology also intersects with emerging work in cancer neuroscience and immune-related neurotoxicity. Cancer neuroscience has drawn attention to the reciprocal relationship between tumors and the nervous system, including neural influences on tumor behavior, tumor-derived effects on neural function, and perineural invasion [3, 4]. Immune checkpoint inhibitor-associated neurotoxicity [5] further illustrates how effective anticancer therapy can produce neurological syndromes requiring joint oncological and neurological decisions. Recognizing these disorders as onco-neurology may support registries and translational studies linking neurological phenotypes with biomarkers, imaging findings, treatment exposure, and outcomes. As cancer care improves and survivorship expands, this field may support more systematic diagnostic approaches and mechanism-based management strategies for patients with neurological dysfunction. Table 1Clinical scope of onco-neurologyCategoryExamplesKey pointParaneoplastic neurological syndromesParaneoplastic encephalitis, cerebellar degeneration, sensory neuronopathy, Lambert–Eaton myasthenic syndromeImmune-mediated neurological disorders associated with cancer rather than direct tumor invasion.Treatment- or procedure-related neurological injuryChemotherapy-induced peripheral neuropathy, radiation injury, targeted therapy-related toxicity, postoperative or biopsy-related neurological injuryNeurological dysfunction related to anticancer treatment or diagnostic/therapeutic procedures.Immune-related neurological adverse eventsEncephalitis, myelitis, neuropathy, myasthenia-like syndromes after immune checkpoint inhibitors; CAR-T-related neurotoxicityTreatment-induced immune activation requiring joint decisions on immunosuppression and anticancer therapy.Systemic or tumor-associated neurological dysfunctionMetabolic encephalopathy, endocrine disturbance, cytokine-mediated symptoms, cachexia-related weakness, tumor-derived effectsNeurological symptoms driven by systemic cancer-related processes or tumor-associated biological effects. Table 1Clinical scope of onco-neurologyCategoryExamplesKey pointParaneoplastic neurological syndromesParaneoplastic encephalitis, cerebellar degeneration, sensory neuronopathy, Lambert–Eaton myasthenic syndromeImmune-mediated neurological disorders associated with cancer rather than direct tumor invasion.Treatment- or procedure-related neurological injuryChemotherapy-induced peripheral neuropathy, radiation injury, targeted therapy-related toxicity, postoperative or biopsy-related neurological injuryNeurological dysfunction related to anticancer treatment or diagnostic/therapeutic procedures.Immune-related neurological adverse eventsEncephalitis, myelitis, neuropathy, myasthenia-like syndromes after immune checkpoint inhibitors; CAR-T-related neurotoxicityTreatment-induced immune activation requiring joint decisions on immunosuppression and anticancer therapy.Systemic or tumor-associated neurological dysfunctionMetabolic encephalopathy, endocrine disturbance, cytokine-mediated symptoms, cachexia-related weakness, tumor-derived effectsNeurological symptoms driven by systemic cancer-related processes or tumor-associated biological effects. Clinical scope of onco-neurology